果酱视频

Key Highlights:

• US prices of Terbinafine hydrochloride rebounded significantly in September 2025 from its August decrease due to bulk buying in anticipation of tariffs.
• Trump's September 25th statement: 100 percent tariff on labeled drugs arriving from October 1, unless US factories are being set up.
• Policy triggered stockpiling frenzy, boosting Terbinafine hydrochloride costs in the aftermath of $252 B US pharma imports from majorly Asian nations.
• Q4 projections indicate further price increases for Terbinafine as small distributors experience margin pressures and shipping problems.
• Pharma move to US manufacture for relief, with near-term volatility still in generics such as Terbinafine hydrochloride.

US market prices of Terbinafine hydrochloride, a crucial antifungal drug, in September 2025 reversed their August fall on the momentum of seasonal demand and a dynamic trade policy adopted by the Trump administration. The phenomenon has monumental implications for the pharma industry, especially for medicine like Terbinafine hydrochloride, which is employed to cure chronic fungal infection.

Terbinafine hydrochloride typically experiences steady, round-the-clock demand since fungal infections are long-lasting. After the August price drop due to realignments in the supply chain, September saw a quick rebound. Increased procurement activity and supply chain reconfigurations contributed, but the deciding factor was a developing US trade policy. On September 25, US President Trump announced a 100% tariff on imported branded and patented medicines from October 1, unless manufacturers establish local production facilities. It triggered a spate of bulk orders in large quantities by consumers to stock Terbinafine hydrochloride and other medicines to pre-empt the incoming tariffs, driving prices higher steeply.

US pharmaceutical industry, which received $252 billion worth of drugs in the last year largely from Asia, stands to experience major dislocations. Tariff policy promises price shock and possible shortages of popular prescription medicines such as Terbinafine hydrochloride. Industry analysts predict a spectacular fourth-quarter price shock as distributors and importers prepare to the new tariff policy. Small distributors would be most affected by trimmed profit margins and logistics woes in acquiring inventory levels, further generating market volatility.

The October 1 deadline is a cut-theory point for the global pharma supply chain. Previous hints from the Trump administration, most recently in July, when 200% tariffs were proposed as an option, signaled a hard-line policy toward using the pharmaceutical industry in trade negotiations. While the increased tariffs were not permanently imposed, their potential is changing supply and price structures for critical medicines such as Terbinafine hydrochloride.

Pharma firms are now reviewing their strategy, with some considering domestic production to counter the impact of tariffs. But changing gear to domestic production is a lengthy, complicated process, and in the meantime the market is vulnerable to short-term price instability and supply upset. The imperative to localize will ultimately reshape the global supply chain, but in the meantime the players have to deal with an unfavourable regime of escalating costs and possible disruption. Meanwhile, as the market is rebalancing, the price and supply of Terbinafine hydrochloride will be closely observed in the months ahead.